The Research

This 12-month, multicenter, open-label study evaluated the long-term safety and efficacy of triamcinolone acetonide (TAA) aqueous nasal spray for treating perennial allergic rhinitis (PAR). The study followed patients who had participated in a prior 4-week, double-blind trial and assessed symptom relief and adverse events over an extended period. Patients either continued on TAA or switched from placebo to TAA for the duration of the study.

This multicenter, prospective, randomized, open-label study assessed the long-term safety of intranasal triamcinolone acetonide (TAA) aqueous spray in patients with perennial allergic rhinitis (PAR). The primary focus was on nasal mucosal integrity over six months of treatment.

This one-year, open-label extension of a prior 12-week, double-blind clinical trial assessed the long-term safety and efficacy of once-daily triamcinolone acetonide nasal aerosol in 93 patients with perennial allergic rhinitis (PAR). Patients received one of three daily doses: 110, 220, or 440 micrograms.

This comprehensive review explores the mechanisms, pharmacokinetics, and safety profiles of intranasal corticosteroids (INSs), which are widely used to treat allergic rhinitis, rhinosinusitis, and nasal polyposis. The paper highlights the development of newer corticosteroid molecules that provide potent local anti-inflammatory effects with minimal systemic absorption.

This multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of triamcinolone acetonide (TAA) aqueous nasal spray in 178 patients with perennial allergic rhinitis (PAR). Participants were treated once daily for 4 weeks with either TAA (220 mcg) or placebo. Symptom changes were tracked using patient diaries, and efficacy was assessed by both patients and physicians.